pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide (n=69) vs. paclitaxel followed by doxorubicin plus cyclophosphamide (n=181)
randomized controlled trial
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
200mg intravenous pembrolizumab every 3weeks for 4 cycles plus standard NACT: 80 mg/m2 intravenous paclitaxel weekly for 12 weeks, followed by 4 cycles of 60 mg/m2 doxorubicin plus 600 mg/m2 intravenous cyclophosphamide every 2 to 3 weeks (AC).
paclitaxel followed by doxorubicin plus cyclophosphamide
standard NACT: 80 mg/m2 intravenous paclitaxel weekly for 12 weeks, followed by 4 cycles of 60 mg/m2 doxorubicin plus 600 mg/m2 intravenous cyclophosphamide every 2 to 3 weeks (AC).
If patients had an infusion reaction despite corticosteroid premedications, switching to nab-paclitaxel was allowed.
es-BC - HER2 negative - (neo)adjuvant (NA)
stage II or III breast cancer and primary tumors larger than 2.5 cmby clinical examination or larger than 2.0cmby imaging